80% success rate and 20% failure rate in 1750 patients followed up to 6 months. Success dropped to 75% and failure increased at 25% in 1400 followed up to 18 months.
Prospective, double blind, RCT; Ozone + ESI vs ESI alone.
75% of patients were able to avoid surgery, and of the patients that avoided surgery, 82% improved at 5 years, and 88% improved at 10 years. 79% of patients had a reduction in herniation volume and the average reduction was 56%.
62.5-85% in terms of leg pain relief.
The likelihood of showing improvement on the modified MacNab
scale was 79.7%.
9 superior, 3 equivalent to control, 3 not assessed.
71% of patients avoided surgery. Non-inferior to microdiscectomy surgery.
We have recently welcomed Jodi Menezes to SpinaFX as Head of Clinical Affairs. Jodi joins us from Johnson & Johnson, with a decade of experience in the MedTech industry, where she has built a strong foundation in driving business growth, operational efficiencies, and strategic market expansion. In her role as Head of Clinical Affairs at
April 10-12, 2025 SpinaFX was honored to participate in the 33rd Interdisciplinary Research Conference on Injectable Osteoarticular Biomaterials and Bone Augmentation (GRIBOI), held at the Fairmont Banff Springs Hotel in Banff, Alberta, Canada. At Booth #3, our team engaged with interventional spine and pain specialists, researchers, and industry leaders from
Banff, Alberta, Canada SpinaFX, a Canadian company focused on developing minimally invasive, image-guided treatments for back pain caused by contained herniated discs, proudly participated in the 33rd Interdisciplinary Research Conference on Injectable Osteoarticular Biomaterials and Bone Augmentation (GRIBOI 2025). Held from April 10 to 12 at the Fairmont Banff Springs